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Melissa Davis7, Adam J. de Smith8, Julie Dutil9, Jane C. Figueiredo10, Rena Fox1, Kristi D. Graves11, Scarlett Lin Gomez2,12, Andrea Llera13,
Susan L. Neuhausen14, Lisa Newman7,15, Tung Nguyen1, Julie R. Palmer16, Nynikka R. Palmer17, Eliseo J. Pérez-Stable18,19,
Sorbarikor Piawah1,20, Erik J. Rodriquez18, María Carolina Sanabria-Salas21, Stephanie L. Schmit22, Silvia J. Serrano-Gomez23,
Mariana C. Stern24, Jeffrey Weitzel14,25, Jun J. Yang 26, Jovanny Zabaleta27, Elad Ziv1 and Laura Fejerman 1
There are well-established disparities in cancer incidence and outcomes by race/ethnicity that result from the interplay between
structural, socioeconomic, socio-environmental, behavioural and biological factors. However, large research studies designed to
investigate factors contributing to cancer aetiology and progression have mainly focused on populations of European origin. The
limitations in clinicopathological and genetic data, as well as the reduced availability of biospecimens from diverse populations,
contribute to the knowledge gap and have the potential to widen cancer health disparities. In this review, we summarise reported
disparities and associated factors in the United States of America (USA) for the most common cancers (breast, prostate, lung and
colon), and for a subset of other cancers that highlight the complexity of disparities (gastric, liver, pancreas and leukaemia). We
focus on populations commonly identified and referred to as racial/ethnic minorities in the USA—African Americans/Blacks,
American Indians and Alaska Natives, Asians, Native Hawaiians/other Pacific Islanders and Hispanics/Latinos. We conclude that even
though substantial progress has been made in understanding the factors underlying cancer health disparities, marked inequities
persist. Additional efforts are needed to include participants from diverse populations in the research of cancer aetiology, biology
and treatment. Furthermore, to eliminate cancer health disparities, it will be necessary to facilitate access to, and utilisation of,
health services to all individuals, and to address structural inequities, including racism, that disproportionally affect racial/ethnic
minorities in the USA.
British Journal of Cancer (2021) 124:315–332; https://doi.org/10.1038/s41416-020-01038-6
BACKGROUND
Considerable progress has been made over the past decade in
describing cancer health disparities by racial/ethnic categories,1–5
as well as implementing changes regarding how racial/ethnic
groups are defined. In the context of this review, we use the terms
‘race/ethnicity’ or ‘racial/ethnic minority populations’ to refer to
what we know are heterogeneous groups of people defined by
the USA Office of Management and Budget as African Americans/
Blacks (AA/B), American Indians and Alaska Natives (AI/AN), Asians,
Native Hawaiians/other Pacific Islanders and Hispanics/Latinos.6
We understand that these categories are socially constructed and
relevant for the USA population based on their use within official
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registries, health systems and the decennial census.7 Because
great diversity exists within broad racial/ethnic categories, studies
from the past 15 years that report cancer incidence and outcomes
often include subpopulation analyses by geography, country of
origin, socioeconomic status (SES) or genetic ancestry.2,8–22
Research into health disparities has shifted from single-
dimension models to complex frameworks that incorporate
multiple domains (biological, behavioural, physical/built environ-
ment, sociocultural environment and healthcare system) and
levels of influence (individual, interpersonal, community and
societal).6,23–27 These ecosocial/multilevel frameworks attempt to
provide a thought structure that integrates ‘biology’ and ‘social’
analyses to bring about new hypotheses instead of simply trying
to combine or interpret associative results obtained within these
different dimensions.27 However, progress in understanding the
mechanisms (moving from association to causality) and subse-
quent reduction or elimination of disparities has been relatively
slow. The slow rate of progress has been partly due to the lack of
adequate support, data and biospecimen availability for research
focused on diverse populations. Studies that combine biospeci-
men collection with measures of individual behaviour, physical/
built and sociocultural/socioeconomic environment can be
expensive due to the fact that these studies have to be large
enough to be able to assess the independent and joint effects of
these factors, and for distinct racial/ethnic groups. The develop-
ment of large and prospective cohort studies, such as the
Multiethnic Cohort (MEC) study (Box 1) has been rare, given the
high costs associated with the infrastructure requirements for
recruitment, baseline measures and long-term follow-up of a large
number of participants from different race/ethnicities. These
challenges, combined with limited immediate statistical power
for subgroup analyses, add to the paucity of adequately diverse
datasets for cancer research.28–31 Fortunately, current funding and
resource development efforts, as well as ongoing international
collaborations, aim to improve our knowledge of the basis of
health/disease in diverse populations.19,32–40 Additional and
continuous investments will be necessary to support studies that
capture multidimensional and multilevel data, and allow a deeper
understanding of how different factors interact to contribute to
the observed cancer health disparities.
We begin our review by outlining factors that are commonly
described as contributing to health disparities for multiple cancer
types. Additional sections focus on the most common types of
cancer (breast, prostate, colorectal and lung), and a selection of
other cancer types that illustrate how different factors can
contribute to disparities (gastric, liver, pancreas and leukaemia).
Our overall aim is to provide a summary of some of the known
cancer health disparities by race/ethnic categories in these
selected cancer types, and the proposed contributing/associated
factors. This is not an exhaustive review, and additional literature
on health disparities for other cancer types, such as melanoma,
bladder or ovarian cancer, can be found elsewhere.41–43 In the
’Conclusions‘ section, we describe suggested actions (Box 2) that
could contribute to the elimination or reduction of cancer health
disparities.
FACTORS THAT CONTRIBUTE TO HEALTH DISPARITIES FOR
MULTIPLE TYPES OF CANCER
Cancer health disparities affecting diverse populations in the USA
are the consequence of the interplay of many factors. Some of
them, such as those related to structural inequities, can lead to
disparities observed in multiple types of cancer. This section
provides a brief overview of some of those factors.
Healthcare
The USA healthcare system is a combination of publicly and
privately funded systems and programmes. The majority of
Americans are covered by private insurance plans through their
employers, and public programmes, such as Medicaid and
Medicare, provide coverage to individuals with limited income
and resources.44 However, even after the implementation of the
Affordable Care Act in 2010, millions of Americans remain
uninsured, with Hispanics/Latinos being the most affected
group.44,45 In addition, few USA systems offer integrated care
(e.g. the Kaiser Permanente model); under most health insurance
companies or programmes, it is up to the patient to identify
doctors and specialists and coordinate their own care. Racial/
ethnic minorities are known to be disproportionally affected by
this approach,44 due in part to cultural and language barriers.46
Socioeconomic status
Self-reported race/ethnicity correlates with SES,47 and, in turn, low
SES has been associated with poor access to high-quality care,
lower screening rates, delays in treatment after diagnosis and
lower treatment adherence.48 Cancer health disparities between
racial/ethnic minorities and Non-Hispanic Whites (NHWs) can be in
part explained by these associations.49–53 Furthermore, financial
distress associated with cancer management prevents adequate
care, starting prior to diagnosis, during imaging and through
pathological confirmation.54,55 Whereas effective advances in
multidisciplinary cancer care have contributed to improved survival
rates, the costs of these treatments and the concomitant impact of
some treatments on employment/disability disproportionately
burden those patients who are socioeconomically disadvantaged,
many of whom are AA/Bs and Hispanics/Latinos.54,56,57 However,
SES is not the only dimension to consider when thinking about
disparities affecting racial/ethnic minorities—additional factors are
associated with SES but not fully encompassed by it. For example,
among immigrant populations who have not long been in the
USA, limited English proficiency can be an additional barrier to
accessing healthcare services.58–63
Box 1: The Multiethnic Cohort (MEC) study366
● The MEC is a large epidemiological study created in 1993–1996 and financed
by the USA National Cancer Institute. It includes over 215,000 men and
women primarily of five racial/ethnic groups: Non-Hispanic White, Japanese
American, Native Hawaiian, African American and Hispanic/Latino partici-
pants.
● Main goal: MEC study aims to understand racial/ethnic differences in cancer
as well as other chronic diseases, to contribute in correcting health disparities
and prevent cancer and other diseases in all populations.
● Resources: MEC collects baseline information through extensive question-
naires encompassing demographic, lifestyle, dietary, environmental and
genetic risk factors, and performs follow-up questionnaires over time.
Biological specimens (mainly blood and urine) have been collected from
~70,000 participants.
Box 2: Summary of suggested actions to advance research and
reduce/eliminate cancer health disparities
● Further develop and sustain large diverse cohorts that collect multidimen-
sional/multilevel data.
● Diversify germline and tumour genetics/genomics databases and clinical
trials.
● Develop diverse cell lines and patient-derived xenograft models.
● Implement system changes in healthcare coverage to guarantee equity in
access to high-quality screening and access to treatment.
● Improvement and system-wide implementation of patient navigation
programmes.
● Employ culturally tailored community awareness and education programmes
to increase cancer screening (including genetics) and modify risk behaviours.
● Implement legislation that supports behavioural interventions (e.g. limit the
sales of tobacco products).
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Other risk factors (modifiable and non-modifiable)
The relatively high prevalence of certain underappreciated
exposures might also contribute to a higher incidence of different
types of cancer. For example, AA/Bs and Hispanics/Latinos in the
USA are more likely to live in low-income areas that are exposed
to higher levels of environmental pollution.64–69 Independent of
SES, individuals from racial/ethnic minorities might be exposed to
socio-environmental conditions and stressors that affect health
outcomes throughout the course of life. For example, structural
and interpersonal racism can translate to a higher risk of
psychosocial stressors.47
In addition, disparities observed for some types of cancer are
also explained by differential incidences of infections or diseases
by race/ethnicity, such as cytomegalovirus (CMV) infection for
childhood acute lymphoblastic leukaemia,70,71 and hepatitis B
(HBV) and HCV for liver cancer.72,73
Previous studies point to further stratification of cancer
incidence and mortality in diverse populations based on birthplace.
Some studies on breast cancer15,16 and prostate cancer15,74–76 have
shown that incidence and mortality rates are different among
different Latin American countries. Differences have also been
observed for different populations of AA/Bs.77 Some cancer types
show a higher rate of cancer-specific mortality in second- and
third-generation immigrants compared with their foreign-born
counterparts.10,77–81 These findings suggest that the adoption of
certain behaviours (e.g. changes in diet or reproductive behaviour)
or environmental exposures that are more prevalent in the USA
might lead to an increased risk of mortality for certain cancers.82–95
Because the country of origin is missing for a large proportion of
cancer patients in the Surveillance, Epidemiology and End Results
(SEER) Program data, descriptive analyses on incidence and
mortality by country of origin based on this resource must be
interpreted with caution.96
Substantial evidence has shown that unequal cancer burden
among populations of different races/ethnicities can be partially
explained by their population-specific genetic background or
genetic ancestry.49,97,98 For example, Hispanics/Latinos are part
of a genetically diverse ethnic group with varying proportions of
Indigenous American, European, African and to a lesser extent,
Asian ancestry components.99 Inclusion of genetic ancestry in
studies focused on the molecular biology of cancer in admixed
populations is essential to prevent confounding.100 Genetic
ancestry in admixed populations can also be leveraged to
identify ancestry-specific biology,101,102 and provide insights
into observations such as the disproportionally higher incidence
of triple-negative breast cancer (TNBC) and aggressive prostate
cancer in AA/Bs, or lower incidence of breast cancer in
Hispanics/Latinas.102–105
Race/ethnicity and SES are highly correlated, and often they are
studied separately.106 After adjusting for SES, disparities in cancer
risk and outcomes are reduced but not eliminated.106,107
Intersectional approaches that focus on the complex interaction
of social determinants with other factors that are experienced
simultaneously, can provide an opportunity to disentangle their
joint effect on the observed disparities.108
DISPARITIES IN BREAST CANCER
Incidence and mortality
Age-adjusted breast cancer incidence varies by race/ethnic
category, being the highest in White individuals (131.3/100,000),
followed by AA/Bs (124.8), Asians and Pacific Islanders (102.9),
Hispanics/Latinos (99.1) and AI/ANs (79.5).109 It is notable that
although breast cancer incidence has historically been relatively
low among Asian groups,110 it has been increasing over the past
30 years.57,110 The few reports that have disaggregated the
incidence and mortality of breast cancer among Asian subgroups
have shown strikingly variable rates and trends.13,110,111
Similar variation has been observed for different Hispanic/Latino
populations.15
AA/B, AI/AN and Hispanic/Latina women have a higher risk of
breast cancer-specific mortality relative to NHW women.112–117
This increased risk is consistent with studies describing a more
advanced stage at diagnosis,21,112 lower treatment adher-
ence,118 limited access to high-quality care119 and a higher risk
of developing the most aggressive subtypes of breast cancer
among individuals from racial/ethnic minorities compared with
NHWs.114,120–124
Disease subtypes
AA/B women of West African descent and Hispanics/Latinas in the
USA and abroad are more likely to be diagnosed with hormone-
receptor-negative (HR–) tumour phenotypes than patients
from other populations.56,57,121–123,125,126 Hispanics/Latinas and
Asian women are also at increased risk of being diagnosed with
human epidermal growth factor receptor 2-positive (HER2+)
disease.18,19,121–123,125 AA/Bs are twice as likely as NHW women
to have TNBC (indicating the lack of oestrogen receptor [ER],
progesterone receptor [PR] and HER2).19 TNBC is one of the most
aggressive subtypes of breast cancer, with as yet no targeted
treatment. The higher incidence of HR– breast cancer in AA/B
women and Hispanics/Latinas might be due to different levels of
exposure to environmental and lifestyle factors that play a role in
the aetiology of this type of breast cancer. Evidence shows that
higher parity in the absence of breastfeeding is associated with an
increased risk of HR– breast cancer,93 and in the USA, breastfeed-
ing prevalence is markedly lower in AA/B women than in other
populations.93,94 Furthermore, type 2 diabetes and obesity, which
are more common in AA/B and Hispanics/Latinos than NHWs,127
can also increase the risk and progression of breast cancer,
particularly HR– breast cancer.84,91,92 Insulin resistance, a risk factor
for prediabetes and type 2 diabetes, promotes weight gain and in
turn induces tissue inflammation.128 Inflammatory cytokines and
associated immune cells involved in this process activate
signalling pathways that promote more aggressive TNBC pheno-
types.128 In addition, AA/Bs and Hispanics/Latinas are more likely
to live in low-income areas with higher exposures to environ-
mental pollution, and emerging epidemiology evidence supports
a possible role for hazardous air pollutants, traffic emissions and
radon in breast cancer, particularly HR– breast cancer.64,65
The specific factors contributing to the higher prevalence of
HER2+ breast cancer in Asians and Hispanics/Latinas are
unknown. However, a study reporting a positive association
between the proportion of Indigenous American ancestry and
HER2 status in breast cancer patients from Peru, Colombia and
Mexico suggested that germline genetic variants associated
with this component of ancestry might play a role.129 It is also
possible that other, as yet unknown, factors that are highly
correlated with ancestry proportions in these populations can
explain the observed association.129
Genetic variants
Genome-wide association studies (GWAS) have discovered several
loci associated with an increased risk of breast cancer;130–135
however, these variants have been primarily described in
European populations, while other populations remain under-
represented.29 GWAS hits have been replicated in Hispanic/Latino
populations but poorly in AA/B populations, probably due to
distinct linkage-disequilibrium patterns.136 The predisposition to
breast cancer by common genetic variants differs according to
genetic ancestry,105,137 and ongoing efforts are aimed at detecting
population-specific risk variants for breast cancer in AA/B,138–140
Asian141,142 and Hispanic/Latina105,138 women. The presence of a
single-nucleotide polymorphism (SNP) at 6q25 among Hispanics/
Latinas is associated with a lower risk of breast cancer, especially
HR– subtypes.8,101,143 In addition, risk variants that are more
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common in women of African genetic ancestry have been
reported to be associated with HR– disease.139,140 One of these
SNPs is located within TERT (telomerase reverse transcriptase),139
a known cancer-susceptibility gene. However, the molecular
mechanisms underlying the observed associations are not
yet clear.
GWAS-identified SNPs with small individual effects can be
combined into polygenic risk scores (PRS) to predict cancer risk.
Given the limited availability of racial/ethnic diverse samples, PRS
generated with SNPs discovered mostly in European or Asian
populations are being tested for their predictive power among
individuals from other groups.37,144,145 The results suggest that, as
currently calculated, these PRS are less predictive of cancer risk in
individuals with high African ancestry,144,145 but are equally
predictive among Hispanics/Latinas, even in those of high
Indigenous American ancestry.37 SNPs discovered in European
populations can, therefore, be used to predict the risk of breast
cancer in non-Caribbean Hispanics/Latinas, thus widening the
application of PRS.
Regarding high-penetrance mutations associated with an
increased risk of breast cancer, Hispanics/Latinas from certain
regions might have higher rates or a different set of mutations
compared with NHWs.146–150 Although the frequency of BRCA
mutations in AA/Bs is lower than the frequency in Hispanics/
Latinos and non-Ashkenazi Jewish NHWs, AA/Bs have higher rates
of variants of unknown significance (VUS),151 comparable with the
frequency observed among Asians.152,153 Over time (within
months to years of their initial classification), as more information
is gained about normal human genomic diversity, most (90.3%)
VUS are downgraded to benign/likely benign variants; only 7.5%
of the VUS are reclassified as pathogenic/likely pathogenic.154 This
evidence highlights the need for additional genetic/genomic
studies to understand the significance of unclassified variants in
diverse ancestry groups.
Tumour biology
Differences in tumour biology according to race/ethnicity have
also been described. Studies have found differences in gene
expression155–157 and methylation patterns158–161 between AA/Bs
and NHWs, which might have a potential impact on patient
outcomes.156–160,162 Most of these findings are more evident for
young, HR– patients.155,158,161 Other features, such as a differential
mutational landscape157,163 and higher frequency of DNA copy
number alterations,161 have been reported for AA/Bs compared
with NHWs, in addition to the existence of differential immune
and inflammatory pathways involved in tumour-specific immune
responses between the two groups.164,165 As stated above, obesity
is associated with increased circulating levels of insulin and
inflammatory cytokines, such as IL-6, IL-8 and TNF-α and CD8+
T cells and M1 macrophages, which contribute to the develop-
ment of a pro-tumorigenic microenvironment and more aggres-
sive tumour characteristics, leading to TNBC biology in AA/B
women.128,166 Breast cancer research that is focused on the
interplay between race/ethnicity, poverty, diet, obesity and
aggressive tumour biology exemplifies the richness and complex-
ity of hypotheses that result from the use of ecosocial/multilevel
theoretical frameworks.
Few studies have evaluated differences in tumour biology
among Asians or Hispanics/Latinas compared with NHWs.167–169
One study, based on the TCGA database, described the differential
activation of several cancer-related pathways between Asian
Americans and NHWs.167 Another study compared a Korean breast
cancer cohort with NHWs from the TCGA, and found differences in
mutational profiles and other differences driven by features
associated with the tumour microenvironment, leading to a more
immune-active tumour microenvironment among Asians.168
A small study using Oncotype DX169 suggested that CCNB1 and
AURKA genes are highly expressed in Hispanics/Latinas, and that
Hispanics/Latinas with early-stage HR+/HER2– tumours have
increased proliferation compared with NHWs.169 For other
populations, more studies are needed to address disparities, with
a focus on tumour biology beyond genetics.
DISPARITIES IN PROSTATE CANCER
Incidence and mortality
Prostate cancer is the number 1 cancer affecting men in the USA,
accounting for 20% of all cancers, and the second highest cause of
cancer-related deaths, with 33,330 men predicted to die of this
disease in 2020.2 In more than 80% of men diagnosed with
prostate cancer, the disease will be localised, indolent and, if left
undetected, would be harmless. However, a significant subset of
prostate tumours will be aggressive and can lead to death.
Interestingly, prostate cancer incidence rates have declined over
the past 10 years, which might be due in part to the US Preventive
Services Task Force (USPSTF) recommendation170 in 2012 against
routine screening because of concerns of overdiagnosis and
overtreatment, as well as other undefined factors.171 A shift
towards increases in metastatic and lethal prostate cancer appears
to be occurring,172 especially among younger AA/B men.173 Due
to early detection and treatment advances, mortality from
prostate cancer has decreased over the past two decades by
51%,48 but, unfortunately, this improvement has not benefited all
equally, as racial and ethnic disparities persist.
Prostate cancer disparities constitute the largest of all cancer
disparities. AA/B men suffer disproportionately from prostate
cancer, facing a 78% higher incidence rate than NHW men.2 AA/B
men are also more likely to be diagnosed at a younger age,
present with more advanced and aggressive disease and have a
2.3-times higher mortality rate compared with NHW men.2,174,175
Although the incidence rates for prostate cancer are lower in
Hispanics/Latinos and some Asian groups than in NHW men,174
Hispanics/Latinos are more likely to present with more advanced-
stage disease.176
The incidence of prostate cancer also varies among different
racial/ethnic populations based on the place of residence or
country of origin. For example, among Hispanics/Latinos, the
incidence is lower for Mexican Latinos than Caribbean
Latinos.15,74–76 Inhabitants of Puerto Rico have lower incidence
rates than Puerto Ricans living in mainland USA.177 Hawaiians/
Samoans living in Los Angeles have incidence rates of prostate
cancer higher than NHWs living in Los Angeles, followed by
Filipinos and Japanese, who have a lower incidence than NHWs
but a higher risk than other Asian groups.1 Although patients
from some Asian subpopulations have better survival rates than
NHW patients, they are more likely to present with advanced
disease and metastatic prostate cancer, particularly those who
are foreign-born.48,178,179 This contradictory behaviour is yet not
well understood; however, the authors speculate that this might
be attributable to biological and lifestyle factors.179
Potential aetiological factors
Few established risk factors exist for prostate cancer. Among them
are non-modifiable risk factors such as age, African genetic
ancestry, family history of prostate cancer and common genetic
variants.180–182 AA/B men not only have a higher risk of
developing prostate cancer, but they tend to have a more
aggressive disease. Several genetic variants at the 8q24
locus183,184 and other loci185 are more common in AA/B men,
and might explain some of the differences in incidence and
outcome between AA/Bs and NHWs. In addition, a mutation in a
prostate cancer tumour-suppressor gene (EphB2) was reported to
have a higher frequency among AA/B men, which may also
explain the role of family history and African ancestry in increasing
the risk of prostate cancer.186 Differences in microRNA regulation
may also contribute to exacerbate the observed increased
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aggressiveness of tumours among AA/B men.187 Furthermore,
tumour gene mutations that are common among NHWs, such as
PTEN and TMPRSS2–ERG fusions, might be less prevalent among
AA/Bs, and novel mutations have been reported in genes not
previously thought to play a key role in prostate cancer, such as
CDC27–OAT fusion and ERF.188–190 The most recent study with
tumour and follow-up data suggests that copy number alterations,
TP53 somatic mutations and deletions in CDKN1B may be
associated with poor outcome among AA/B men.191 The tumour
mutational landscape of AA/B and Hispanic/Latino prostate cancer
patients needs to be better characterised. Altogether, fewer than
~250 prostate tumours from AA/Bs have been studied, and to our
knowledge, no tumours from Hispanics/Latinos are included in
existing characterisation studies.31
Other probable modifiable risk factors include calcium,
vitamin D and lycopene intake,192 body fatness193 and red meat
intake,194 which are known to vary by racial/ethnic groups.195,196
Among Hispanics/Latinos, exposure to agrichemicals has also
been reported as a risk factor.197,198
Healthcare: screening and treatment
The excess burden of prostate cancer borne by AA/B men should
be an urgent public health priority. Men of African descent have
essentially been unrepresented in prostate-specific antigen (PSA)
screening trials, but rigorous modelling studies carried out in 2017
have shown that PSA screening can yield greater mortality
benefits for high-risk groups, especially AA/B men.199 Early
detection remains paramount, and individuals can benefit from
PSA-based screening as currently recommended by the
USPSTF.200 A high midlife (mid-to-late 40s) baseline PSA test
strongly predicts the likelihood of developing lethal prostate
cancer in the future, particularly among AA/B men, and
conversely, a low value rarely leads to aggressive prostate cancer
in the future, and can therefore minimise the need for screening in
low-risk men.201,202 However, early detection alone will not
eliminate the disparities in prostate cancer. How the complex
interplay between social factors (e.g. racism) and biology (e.g.
genomic differences) contributes to prostate cancer disparities has
not been clearly elucidated. A need for multilevel data exists, as
does the need to develop approaches to identify risk factors and
reduce them, by fully engaging all stakeholders, including
patients, providers, community members and organisations and
healthcare systems.203
Access to, and utilisation of, healthcare is a key factor in racial/
ethnic disparities. For example, the reported overall lower
incidence among AI/AN and Hispanics/Latinos might be explained
by lower PSA screening rates compared with NHW men,204–206
raising concerns about under-detection in these populations. This
lack of early detection contributes to higher mortality, particularly
among AI/AN men.207 Standard prostate biopsies are key to
diagnosis and cancer staging.208 However, this approach is limited
in its ability to accurately visualise and target prostate lesions, and
is thereby prone to under-sampling and under-diagnosis of
clinically significant prostate cancer. Multiparametric MRI-guided
biopsy sampling can address these challenges,209 but this
procedure is less likely to be available to low SES patients.210
The rate of under-diagnosis seems to be the highest for AA/Bs,
followed by Hispanics/Latinos and then NHWs.211–213
Individuals from racial/ethnic minority populations and unin-
sured patients are more likely to experience delays in treatment
than insured, NHW individuals,48,53 and the treatment for AA/B
men with high-risk/aggressive prostate cancer is less likely to be
definitive (involving surgery or radiation); these disparities are the
greatest in low-income communities.214 Furthermore, men from
racial/ethnic minority populations and those on a lower income
reported worse bowel and urinary function and more sexual
dysfunction than NHW men after radical prostatectomy or
radiation, which might reflect poorer-quality treatment and
follow-up care, as well as the disadvantages prior to treatment.215
Given that most cases of prostate cancer are localised, adequate
risk stratification at the time of biopsy is critical to avoid
treatments that impact the quality of life, and to ensure that
aggressive tumours receive definitive treatment. Unfortunately,
current risk stratification biomarkers and risk models do not
adequately represent diverse populations.103
DISPARITIES IN LUNG CANCER
Incidence and mortality
Lung cancer is the leading cause of cancer mortality in the USA;
however, the incidence and mortality rates for lung cancer vary
substantially by self-reported race and ethnicity. AA/B men have
the highest incidence rate (71.2/100,000 people) compared with
other racial/ethnic groups (35.1–65.3).216 Among women, the
lowest incidence rates have been observed in Hispanics/Latinas
and Asians (24.8 and 28.6 out of 100,000, respectively), which are
about half of those for NHW and AA/B women.216
Smoking and lung cancer incidence
On the basis that tobacco smoking causes 80–90% of all cases of
lung cancer in the USA,217 smoking rates should be a robust
predictor of incidence. However, analyses from the MEC study of
1979 cases of lung cancer showed that for a similar smoking
history of up to 30 cigarettes per day (CPD), AA/Bs and Native
Hawaiians had a significantly higher relative risk (RR) of lung
cancer compared with NHWs (RR= 0.57 for 11–20 CPD),
Hispanics/Latinos (RR= 0.36 for 11–20 CPD) and Japanese
Americans (RR= 0.39 for 11–20 CPD).218 A follow-up analysis
of the MEC study with 4993 cases confirmed the higher rates for
AA/Bs and Native Hawaiians and lower rates for Hispanics/
Latinos.219 When modelling RR from exposure to 50 pack-years,
after adjustment for total nicotine equivalents, the excess risk
for AA/Bs was accounted for, as were the lower risks for
Japanese and NHWs.219 However, the higher risk for Native
Hawaiians and the lower risk for Hispanics/Latinos remained
unexplained.219 Thus, given similar exposure to the same
carcinogen, the rate of lung cancer differed by a factor of 2–3
according to self-reported race/ethnicity.
The optimal strategy for preventing lung cancer is tobacco
control. Some populations have benefitted from the steady
decline of smoking rates in adults over the past 50 years. In
national surveys, Hispanic/Latina women (7%) and women from
some Asian populations (4.6%), and Hispanic/Latino men (14.5%)
and men from some Asian populations (14%), have lower
prevalence of smoking than NHW men (17.8%).220 Variation by
national background occurs with a higher prevalence for Chinese
immigrant men and Puerto Rican mainland women.221,222 AA/B
men are more likely to smoke (20.2%) than NHW men, whereas
smoking prevalence is lower among AA/B women compared with
NHW women (13.5% vs. 15.5%).220 Smoking prevalence is the
highest among AI/ANs (29.3% for men and 34.3% for women), and
recent surveys show similar proportions for persons identified as
being ‘more than one race’.220 Smoking therefore correlates with
the observed incidence of lung cancer, except for the dispropor-
tionate excess risk among AA/B and the lower risk among
Hispanics/Latinos (Fig. 1).218
Other aspects of smoking behaviour might partially explain the
differences in lung cancer incidence: very light (1–5 cigarettes
per day) daily smokers or non-daily smoking among Hispanics/
Latinos,222 smoking topography (puff volume, duration, flow, etc.),
menthol cigarette smoking among AA/B and interactions between
environmental factors and smoking,223 novel alleles in chromo-
somes 2 and 4 associated with non-daily smoking among
Hispanics/Latinos,87 less successful cessation and higher depen-
dence among AA/B88 and low uptake of pharmacological
cessation aids among individuals from racial/ethnic minority
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groups.88 Additional postulated factors include undefined genetic
and epigenetic mechanisms, as well as second-hand smoke, which
is most common among AA/Bs and persons living below the
poverty line.224
Healthcare: screening and treatment
One way to reduce lung cancer mortality, by about 20%, is
through the use of low-dose computed tomography screening
followed by a diagnostic evaluation if the result was abnormal.225
However, the uptake of such screening has been ≤6%,226 despite
it constituting a prevention service for all insured persons. Only
9% of participants in the original trial were from a diverse racial/
ethnic group, and the smoking history eligibility criteria might
have limited the recruitment of diverse, lighter-smoking indivi-
duals.225 Concerns about morbidity owing to the need for
bronchoscopy and biopsy as part of the screening might have
also decreased the uptake, despite endorsement by clinicians.227
Research into screening strategies beyond computed
tomography-led approaches is required, given the existing debate
over the benefits and harms of this technique,228 and the
potential for reducing disparities using life-gained-based eligibility
criteria, which include younger current smokers with fewer
comorbidities. This strategy has been shown to increase life
expectancy per prevented lung cancer death (21.7 vs. 8.9 years,
compared with risk-based strategy alone) and reduce potential
screening-associated harms.229
AA/Bs are diagnosed at a younger age and with more
advanced disease than NHWs. Although Hispanics/Latinos,
especially those foreign-born, show lower mortality rates than
NHWs, they are also diagnosed with more advanced-stage
diseases.230 Both groups are less likely to receive standard
of care,230,231 and to undergo guideline-recommended PET/CT
imaging at diagnosis of non-small-cell lung cancer at all stages,232
and AA/Bs are less likely to be treated with immunotherapy-type
compounds than NHWs, regardless of insurance status.233 These
differences might contribute to the racial differences observed in
survival. The survival rates for AA/Bs are lower than for NHW (16
and 19%, respectively for all stages).174 Nevertheless, under
conditions of equal access to treatment, no differences in survival
prevail,234 reinforcing the need of improving access to quality
care for this population. The survival differences between AA/B
and NHW patients with Medicare diagnosed with early-stage lung
cancer are in part accounted for by a lower rate of surgical
treatment (64% vs. 76.7%) according to SEER Program data.235
Surgical therapy has improved so that early-stage 3 non-small-cell
lung cancer is often amenable to resection, and the persistent
lower rate of surgery for AA/B patients might be amenable to
system interventions.236 Limited data exist on attitudes towards
treatment, stage at presentation and outcomes of therapy in
other diverse populations with lung cancer.
Lung cancer among never smokers is becoming an increasing
problem in populations with low rates of tobacco use, with over
50% of lung cancer cases being diagnosed in never-smoker East
Asian women.237 East Asians are far more likely to be diagnosed
with lung cancer that harbours somatic mutations in the
epidermal growth factor receptor (EGFR) gene;238,239 this has
important implications for treatment as these cancers are more
likely to respond to tyrosine kinase inhibitors240 and prolong life
expectancy by 2 years or more.241 Analyses of Medicare data from
2010 to 2013 showed a relative increase of up to 20% in testing of
these mutations using tissue from lung cancer patients.242 Asians,
women and never smokers were more likely to be tested, and AA/
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Fig. 1 Lung cancer mortality rates and tobacco use among adult men in the United States by racial/ethnic category. Bars in light gray
represent age-adjusted lung cancer mortality rates in the USA for the period 2013–2017216 and bars in dark gray represent tobacco use
among adult men as reported by the 2016 National Health Interview Survey,365 stratified by racial/ethnic category.
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Genetics and tumour biology
Comparative analyses of the molecular features of lung cancer
tissue revealed racial/ethnic differences in genomic profiles,
indicating that the somatic differences observed have genetic
ancestry origins. AA/B patients present higher genomic instability,
more aggressive molecular features244 and higher frequency of
mutations in PTPRT and JAK2 genes compared with NHWs.245
Asians and Hispanics/Latinos also presented different frequencies
of mutations in driver genes compared with NHWs.246,247 Among
Asians, the higher prevalence of mutations in STK11, TP53 and
EGFR genes could explain the better efficacy of PD‐L1 inhibitors in
this population.247 Generating additional data on the frequency of
these mutations by race, ethnicity and genetic ancestry will
advance our understanding of the mechanisms of lung cancer. In
addition, enhancing access to clinical testing for individuals from
diverse populations will be critical for improving the quality of
lung cancer care for all.
DISPARITIES IN COLORECTAL CANCER
Incidence and mortality
Substantial disparities in the incidence and mortality rates for
colorectal cancer (CRC) exist in the USA among racially and
ethnically diverse populations. AA/Bs have the highest incidence
rates of CRC (45.7/100,000) as compared with AI/ANs (43.3), NHWs
(38.6), Hispanics/Latinos (34.1) and some Asian populations (30.0).2
CRC mortality rates follow the same pattern, with the highest rates
observed among AA/Bs (19.0/100,000), followed by AI/ANs (15.8),
NHWs (13.8), Hispanics/Latinos (11.1) and some Asian subpopula-
tions (9.5).2 The underlying factors driving disparities in CRC
mortality have not been conclusively determined, although lower
screening rates, more advanced stage at diagnosis, differences in
treatment patterns and unique tumour biology are all believed to
contribute.76,248–252
Aggregating heterogeneous populations, however, masks the
significant variability that exists in both CRC incidence and mortality
within subgroups. For example, Alaskan Natives experience the
highest CRC incidence and mortality rates among all populations,
and Cubans and Puerto Ricans have disproportionately higher rates
of incidence and mortality than Hispanics/Latinos from other
backgrounds.16,20–22 The mortality:incidence ratio demonstrates
additional disparities that reflect treatment and survival differences
in CRC patients.253 Indeed, the disease in AA/B and Hispanic/Latino
CRC patients is less likely to be localised and regional, and therefore
less amenable to the chance of cure by surgery or radiation,
and more likely to be metastatic, compared with the disease in
NHWs.2,254
Potential aetiological factors
Proposed contributors to the development of CRC include
individual genetic make-up as well as the macro- and micro-
environment that might influence biological behaviour in the
colon.249,255 The distribution of other risk factors for sporadic CRC
might differ between groups, including high-fat/high- caloric
diets, excess body mass index, low physical activity, usage of
tobacco products, alcohol intake, low serum calcium and vitamin
D levels and low fish oil intake.82,83,256 In addition, established
protective factors, such as hormone replacement therapy in
women and the use of aspirin and NSAIDs, are likely to be
different between groups.253,256 Gene–environment interactions
have also been shown to influence the risk of CRC—for example,
the intake of red meat, a known risk factor for CRC, can interact
with genetic variants in some of the key metabolism genes that
are relevant for carcinogen activation and detoxification.257,258
However, very little is known about gene–environment interac-
tions in diverse populations and how, or if, psychosocial,
behavioural or other exogenous agents might affect these
interactions.259
Genetics and tumour biology
The extent to which germline genetics and tumour biology
contribute to racial/ethnic disparities in CRC outcomes has
received limited attention. A few studies to date have investigated
and identified differential responses to cancer therapy and CRC-
specific survival across populations. For example, findings from a
clinical trial of stage III CRC patients suggested that racial/ethnic
disparities in survival persist despite uniform treatment.260 NHWs
experienced better response and greater toxicity from fluorouracil
(FU)-based adjuvant therapy regimens than did AA/Bs, with
differences in the frequency of pharmacogenetic variants across
the populations cited as likely contributors.261,262 Differences in
the prevalence of microsatellite instability/mismatch-repair defi-
ciency, an important molecular feature of some CRCs, might also
affect the response to FU-based therapies.263 Furthermore, a
survival benefit has been observed for chemotherapy and biologic
agents versus chemotherapy alone for NHWs but not for AA/B or
Hispanics/Latino patients.264 Finally, novel somatic mutations
(in HTR1F, FLCN and EPHA6) identified exclusively in AA/B patients
with CRC have been associated with adverse clinical outcomes,
although these results require verification in other cohorts.265
No published data exist specifically for unique driver mutations
among Hispanics/Latinos, AI/ANs, Asians or Hawaiian/Pacific
Islanders. Further studies assessing the interaction between social
(e.g. diet) and biological factors (e.g. gut microbiome, tumour and
immune microenvironment and germline genetics) influencing
CRC incidence and outcome disparities are warranted.
CRC prevention
A key approach to stopping the development of CRC has been the
implementation of prevention strategies, such as those promoting
a healthy lifestyle or medication compliance.266 However, low SES
and restricted healthcare access can limit proven approaches to
prevention and, thus, strategies have not been uniformly applied
across population groups.56,253,267 Interventions such as patient
navigation could overcome these limitations: there is strong
evidence that patient navigation in conjunction with the use of
screening via faecal immunohistochemical tests and/or colono-
scopy can eliminate disparities in the incidence of CRC.268
DISPARITIES IN PANCREATIC CANCER
Incidence and mortality
Pancreatic cancer is uncommon but deadly, with almost 57,600
new cases and 47,050 deaths expected in 2020 in the USA.2
Among the few cancers for which the incidence has been steadily
increasing (1–2% annual increase for more than a decade),
pancreatic cancer also maintains one of the lowest overall 5-year
survival rates of 9% (3% in more than 50% of patients diagnosed
with metastatic disease).2 The lack of sensitive and specific early
detection methods and limited treatment options (only 20% are
eligible to undergo ‘curative’ surgical resection) have contributed
to this poor prognosis. Long-standing and incompletely explained
differences in the rates of pancreatic cancer incidence and
mortality according to race/ethnicity have been documented
since the 1970s.174 The historically low recruitment of minorities in
pancreatic cancer research studies must be remedied to increase
understanding and guide efforts to address these disparities.
AA/Bs have both a higher incidence269–273 and mortality
rate270,271,273–275 compared with NHWs as well as other
populations, which has been documented for both younger
and older adults (<50 years vs. >50 years) across all USA states
other than Hawaii.174,271,272 Nearly all racial/ethnic groups
showed a steady increase in incidence over a 27-year period
from 1988 to 2015, with AI/ANs (who had the lowest incidence
of all race/ethnicity groups) showing the greatest increase over
time and AA/Bs showing stable incidence rates.272 A small study
of diverse individuals in New Mexico suggested that patients
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who self-identified as ‘Native American’ (most likely Navajo) had
a higher mortality risk within 30 days of diagnosis, poorer 5-year
survival and were less likely to receive chemotherapy than
NHWs and Hispanics/Latinos.276
Potential aetiological factors
Behavioural and lifestyle factors that are related to pancreatic
cancer risk and prognosis, including smoking, diabetes, obesity
and alcohol consumption, have been suggested to play a role in
the observed disparities in incidence and mortality, especially
among AA/Bs.89,270 In particular, sudden- onset diabetes has been
reported to increase the risk of pancreatic cancer among AA/Bs
and Latinos.277
The study of genetic factors that might contribute to racial/
ethnic disparities in pancreatic cancer has been limited. There is
some evidence of a higher prevalence of germline and somatic
mutations in the genes encoding cyclin-dependent kinase
inhibitor 2A (CDKN2A) and KRAS Proto-Oncogene, GTPase
(KRAS), in AA/Bs compared with NHWs.278,279 In addition,
the risk genotypes of the P335L and P109S variants of
the somatostatin receptor 5 (SSTR5) gene occur more frequently
in AA/Bs than in NHWs or Hispanics/Latinos, and are also
associated with reduced survival.280 As is the case for other
types of cancer, an exploration of how biological and social
factors interact to contribute to racial/ethnic disparities in
pancreatic cancer is lacking and needed.
Healthcare and treatment
Differences in diagnosis and treatment have been shown to
contribute to some of the observed disparities in survival by
race/ethnicity, especially for AA/Bs.89,270,281,282 Factors such as
older age, minority race/ethnicity, lower SES, being uninsured or
on Medicaid, higher comorbidity index and treatment at a non-
academic centre or a low-volume hospital have been inversely
correlated with receiving standard therapy including
surgery,281,283–288 and are also associated with patient refusal
of treatment.275,289
A study conducted within the Kaiser Southern California patient
population (an integrated system), reported no racial/ethnic
differences with regard to pancreatic cancer treatment and
outcomes.269 This suggests that providing access to high-quality
care to all individuals could eliminate the observed racial/ethnic
disparities in pancreatic cancer survival.
DISPARITIES IN GASTRIC CANCER
Incidence and mortality
Each year, gastric cancer accounts for ~1 million new cancer cases
and ~730,000 cancer deaths worldwide, representing the third
biggest global cause of cancer mortality.290,291 Even though
gastric cancer is relatively rare in NHWs (incidence rates for men of
7.6/100,000 and for women of 3.5/100,000),2 it remains a
significantly disproportionate burden of disease in other popula-
tions, specifically in AA/Bs, Asians, Hawaiian/Pacific Islanders and
Hispanics/Latinos. Data from the SEER Program show that
individuals from these groups are ~1.5–2.0 times more likely than
NHWs to be diagnosed with and die from gastric cancer.290,292–296
Among Asians in California, the highest rates have been reported
among Japanese Americans and Koreans, with the latter showing
double the rate than Japanese Americans and having the highest
incidence rates in the USA.297
The high gastric cancer mortality rate highlights its poor
prognosis. Although early-stage tumours are treatable, the vast
majority of gastric cancers are diagnosed at advanced stages due
to a lack of symptoms and limited early detection
capability.290,298–300 The 5-year survival rate for metastatic gastric
cancer is 5% in the USA.292 The incidence of gastric cancer has
decreased over the past decades due to increased Helicobacter
pylori screening and treatment, together with improvements in
sanitation, hygiene, clean water and food preservation.293
Hispanics/Latinos, Asians and Hawaiian/Pacific Islanders and AI/
ANs on average are diagnosed at an earlier age than NHWs, which
could reflect the difference in the age distribution of these
populations as well as earlier-onset disease.294–296 Hispanics/
Latinos and Asian Americans, which together account for ~25% of
the total US population,301 represent the largest and fastest-
growing US minority populations, respectively.302,303 Notably,
Hispanics/Latinos and Asian Americans are heterogeneous groups
composed of both foreign- and US-born residents. Studies have
pointed to further stratification of cancer incidence and mortality
in these diverse populations based on birthplace.77–81 Data from
California and Texas—states with a high proportion of Mexican
Americans—showed higher mortality rates for Hispanics/Latinos
compared with NHWs, with inverse rates between both states
when comparing foreign- and US-born residents with NHWs.81
Because of the growing demographic impact of these two
minority groups and the known high incidence of gastric cancer
in AA/Bs, gastric cancer defines a leading cause of cancer health
disparities in the USA.
Potential aetiological factors
Differences in exposure to known risk factors for gastric cancer
are likely to contribute to the observed disparities. For example,
H. pylori infection has been associated with the development
of non-cardia gastric cancer,290,298,299 and its prevalence
is higher in racial/ethnic minority populations.296 Likewise,
low-neighbourhood SES was found to be associated with an
increased risk specifically for non-cardia gastric tumours.296
A separate study of SEER data in California found that most
Hispanic/Latino and AA/B patients lived in lower SES neighbour-
hoods when compared with NHWs.295
Gastric tumour subtypes
Hispanics/Latinos, AA/Bs, Asians and Hawaiian/Pacific Islanders are
more likely than NHWs to suffer from non-cardia, diffuse-type
gastric cancer,290,291,296 a histological subtype that is associated
with treatment resistance and poor clinical outcomes, and that is
the main driver of disparities between NHW and USA minority
populations.21
Attempts have been made to further characterise gastric cancer
at the molecular level. TCGA has identified four molecular
subtypes of gastric cancer: Epstein–Barr virus (EBV)-associated,
microsatellite instable (MSI), genomically stable (GS) and chromo-
somally instable (CIN).304 Importantly, these subtypes demon-
strated differences in their therapeutic response: EBV is associated
with a better prognosis, patients with a CIN subtype benefited
most from adjuvant therapy and those with a GS subtype
benefited least from adjuvant therapy and displayed worse
prognosis.305 However, the vast majority of current genomic
resources include samples from NHW individuals,304 and therefore
little is known about the distribution of these subtypes in other
populations. A whole-exome sequencing (WES) pilot study of 28
Latin American patients with gastric cancer found a lower
prevalence of MSI (8% vs. 22%) and CIN (35% vs. 49%) subtypes,
and a higher prevalence of EBV (14% vs. 8%) and GS (45% vs. 19%)
compared with TCGA data, as well as significantly different
frequencies of mutations in known driver genes (ARID1A, PIK3CA
and CDH1) for gastric cancer between the two populations.306
Another study in Hispanics/Latinos from Texas also found that
gastric tumours from these minority populations are enriched for
the GS subtype.307 Together, these data suggest population
differences in the aetiology and molecular subtype between
NHWs and Hispanics/Latinos, many of which might have an effect
on the prognosis and therapeutic response. Further identification
of the distinct molecular mechanisms underlying the aetiology
of gastric cancer in USA minorities will be critical for the
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development of effective treatments and preventive screening
methods to address health disparities in this disease.
DISPARITIES IN LEUKAEMIA
Incidence and mortality
Leukaemia is a malignancy of haematopoietic tissue comprising
four major subtypes: acute lymphoblastic leukaemia (ALL), acute
myeloid leukaemia (AML), chronic lymphoblastic leukaemia (CLL)
and chronic myeloid leukaemia (CML). Of these, ALL shows the
most pronounced racial/ethnic disparity.308–311 For AML, CLL and
CML, incidences are lower in non-NHW populations than in NHWs;
however, AA/B patients have the lowest survival rates for these
malignancies.312 For CLL, AA/B patients present at a younger age
but at a more advanced stage, and have worse survival.313,314
Similarly, AA/B and Hispanic/Latino AML patients are diagnosed at
a younger age, but with a higher frequency of favourable
cytogenetic subtypes, although they have increased mortality
compared with NHWs.315–317 Disparities are also observed among
the less frequent haematologic malignancies, such as multiple
myeloma, with a higher risk among AA/Bs than other racial/ethnic
groups.318,319
ALL is the most common cancer in children, accounting for ~30%
of paediatric malignancies.320 Children of Latin American origin have
the highest risk of ALL in the USA, with age-adjusted incidence rates
~15–40% higher than for NHWs, and with some of the highest
global incidences reported in Latin American countries, including
Mexico and Costa Rica.309–311,321–324 The incidence of childhood ALL
has been increasing in the past decades in the USA, and is rising
fastest in Hispanics/Latinos, with an annual percent change
significantly higher than in other racial/ethnic groups.325 Similarly,
the incidence of adult ALL is the highest in Hispanics/Latinos.326
Moreover, outcomes are generally poorer for both childhood and
adult ALL in Hispanics/Latinos compared with NHWs309,327–331
probably due to disparities in SES,328,332 an increased frequency of
the high-risk Philadelphia chromosome (Ph)-like subtype333–335 and
the increased Indigenous American genetic ancestry in Hispanic/
Latino patients (see below).17
Potential aetiological factors
Germline loss-of-function variants in NUDT15, which confer a
major cause of treatment-related toxicity due to thiopurine
intolerance, are more common in Hispanic/Latino ALL patients
than in NHW patients—in particular, in Hispanics/Latinos with
high Indigenous American ancestry.336,337 Increasing Indigenous
American ancestry has also been shown to be associated with a
greater risk of relapse in children with ALL.17 Genetic risk alleles in
the ARID5B gene, which encodes an oncogenic factor involved in
transcription, have been shown to be associated with increased
Indigenous American ancestry, as well as an increased risk of
relapse, supporting the notion that germline variation influences
both ALL incidence and outcomes.338 Risk alleles in the additional
ALL GWAS loci CEBPE, GATA3 and PIP4K2A were also positively
associated with Indigenous American ancestry.339,340 Furthermore,
five established GWAS-identified SNPs for childhood ALL (ARID5B,
GATA3, PIP4K2A, ELK3 and 17q12) have a >10% higher risk allele
frequency in Hispanics/Latinos than in Europeans in the Genome
Aggregation Database341 compared with one locus (LHPP) that has
a >10% higher frequency in Europeans. In addition, in the
haematopoietic transcription factor gene ERG, a locus was
identified in which SNPs conferred a stronger risk of ALL in
Hispanics/Latinos than in NHWs, with effect sizes of ~1.6 and 1.1,
respectively.342,343 Among Hispanics/Latinos, ERG risk alleles
correlated positively with the extent of Indigenous American
ancestry, and conferred a larger effect on ALL risk with increasing
Indigenous American ancestry, both globally and at the haplotype
level.342,343 Further research is required to determine whether the
ethnicity-dependent effects of ERG might result from interaction
with other genetic or non-genetic factors, and to discover
additional ancestry-related risk loci via admixture mapping and
larger GWAS of ALL in Hispanics/Latinos across all age groups.
Whereas the increased incidence of ALL in Hispanics/Latinos
is thus likely to reflect a greater genetic susceptibility in this
population, rising rates of ALL over a short period of time
implicate environmental exposures. With the exception of ionising
radiation,344 few environmental risk factors have been established
for ALL. Exposure to tobacco smoke, pesticides, paint and other
organic pollutants has shown a modest positive association with
childhood ALL in Hispanics/Latinos and other racial/ethnic
groups.66–69,85,86 Intriguingly, day-care attendance and higher
birth order, proxies for early-life infectious exposure that support
Greaves’ ‘delayed infection’ hypothesis,345,346 have been reported
to confer protection in NHWs but not in Hispanic/Latino
children.347,348 By contrast, however, both Caesarean section and
in utero CMV infection conferred a larger risk of ALL risk in
Hispanics/Latinos.70,95 Determining the mechanisms that underlie
this heterogeneous response to immune-related risk factors, and
examining these in conjunction with the increased burden of ALL
risk alleles in Hispanics/Latinos (e.g. gene–environment interac-
tions), will shed light on the aetiology of ALL.
DISPARITIES IN LIVER CANCER
Incidence and mortality
Although the overall cancer death rate in the USA is declining for
both men and women, the death rate for hepatocellular carcinoma
(HCC) remained the fastest rising cause of cancer-related deaths
from 1999 to 2013.349 The incidence rate of HCC also rose
dramatically during this period, secondary only to that of thyroid
cancer.349 It is two to three times higher in men than in women,349
with American Indian/Alaska natives having the highest rates,
closely followed by Hispanics/Latinos and Asian/Pacific Islanders.217
Among Hispanics/Latinos, USA-born individuals were reported to
have higher incidence rates than foreign-born.350 In California,
Asians have a higher incidence of HCC than do NHWs, AA/Bs and
Hispanics/Latinos, and within Asians, HCC is eight to nine times
more common among Southeast Asians (Laotians, Vietnamese and
Cambodians) compared with other Asian groups.9
Potential aetiological factors
HCC occurs in the setting of chronic liver disease, and any
aetiology of liver disease can increase the risk of HCC. However,
the overwhelming cause of HCC worldwide is hepatitis B (HBV). In
the USA, however, hepatitis C (HCV) has been the primary cause of
the rise of HCC since the 1970s. Together, HBV and HCV infections
account for 78% of cases of HCC in the USA.351 Alcoholic liver
disease, non-alcoholic fatty liver disease (NAFLD) and non-
alcoholic steatohepatitis (NASH) due to diabetes, obesity and
dyslipidaemia, are other major causes.
HCC disparately affects disadvantaged and racial/ethnic minority
populations,73,352 with wide geographic and racial/ethnic variations,
which can be attributed to differential exposure to HBV and HCV, as
well as disparate access to high-quality screening and preventive
care. HBV is the most common cause of HCC among Asians and
Hawaiian/Pacific Islanders.353,354 The rising prevalence of obesity
and the metabolic syndrome, with the consequent increase in
NAFLD, also contributes to the rising incidence of HCC in the USA.
Hispanics/Latinos are disproportionately affected by NAFLD, with
some studies estimating that this disease affects over 40% of USA
Hispanic/Latino population.355
Tumour biology
The most common somatic mutations in HCC include aberrations
in the TERT promoter and the CTNNB1 and TP53 genes.356 Data
from 373 HCC samples from the TCGA database showed that AA/
Bs had the highest frequency (70%) of TP53 mutations compared
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with Asians (36.5) and NWHs (22.8).357 There is no evidence of
racial/ethnic differences in the frequency of CTNNB1 mutations.358
However, CTNNB1-activating mutations are associated with HCC
arising in a background of alcoholic liver disease, and TP53
mutations are commonly associated with HBV-induced HCC.356
Further studies are needed to explore how differential exposure to
risk factors between racial/ethnic groups might affect the tumour
mutational landscape.
Healthcare, prevention and treatment
Despite advances in multimodality therapies for HCC, its prognosis
remains relatively bleak compared with other cancers, with an
estimated 5-year relative survival of 21%.359 Racial/ethnic dispa-
rities exist in the stage of disease at diagnosis as well as survival. A
review of California Cancer Registry data between 1988 and
2012 showed that those individuals least likely to present with
local (early) disease or undergo transplantation for HCC were
Laotian/Hmongs, AA/Bs, AI/ANs and Filipinos.359 The same groups
were also more likely to live in neighbourhoods with the lowest
SES quintile, corroborating the idea that limited healthcare
resources might contribute to later stage at diagnosis and lower
rates of receipt of local/regional curative therapies. Furthermore,
across the USA, AA/B and Hispanic/Latino men have the highest
average person-years of life lost (21 and 20 years, respectively).349
Biomarker-selected therapy or trials for HCC remain limited, as it
is difficult to specifically target known mutations. Therefore, in
order to address the rising incidence of HCC and its associated
morbidity, efforts must focus primarily on the prevention and
control of HBV and on curative therapy for HCV as the primary
underlying aetiologies of HCC. NAFLD poses a major concern for a
rise in HCC in the near future, due to increasing disease
prevalence and the absence of curative treatments. Efforts
focusing on HBV, HCV and NAFLD prevention and treatment
should prioritise populations that are most affected by economic,
language or geography barriers.360–362
CONCLUSIONS
Despite great progress in our understanding of factors that
contribute to racial/ethnic disparities in cancer incidence, tumour
biology and outcomes, disparities still exist, and multidisciplinary
efforts are needed to ameliorate or eliminate them (Box 2).
Federal initiatives have promoted the accrual of diverse
populations in research studies and clinical trials in the USA in
order to increase our understanding of the potential variation in
aetiology, tumour behaviour and treatment response.363,364
However, individuals from diverse racial/ethnic backgrounds still
account for an extremely low percentage of participants.30
Additional efforts should be supported to systematise the detailed
collection of data on biological (including the proportion of
genetic ancestry), behavioural, physical/built environment, socio-
cultural environment and healthcare system factors so that we can
further identify and understand the relevant levels of intervention
that are required to reduce, and ultimately eliminate, cancer
health disparities. Cell lines and patient-derived xenograft models
should also be representative of racial/ethnic diversity to allow
researchers to conduct experiments in genomic and cellular
contexts that better embody human variation.
However, in order to eliminate cancer health disparities,
increasing knowledge about its causes will not be enough. We
need to address the lack of sufficient data to better understand
cancer aetiology and develop appropriate treatments in diverse
populations; also, it is of utmost importance to expand ongoing
culturally and linguistically tailored programmes focused on
cancer awareness, education and navigation, as well as program-
mess to promote behavioural changes in ‘at risk’ groups focused
on already-known modifiable factors. Behavioural changes should
also be supported by structural factors and policies that facilitate
them, such as tobacco control. Finally, and most importantly,
disparities will not be eliminated without the implementation of
system changes that promote health equities, and universal health
insurance coverage (with little or no co-pay) and access to high-
quality care for all.
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